240 related articles for article (PubMed ID: 20124220)
21. APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.
Li Z; Abraham BJ; Berezovskaya A; Farah N; Liu Y; Leon T; Fielding A; Tan SH; Sanda T; Weintraub AS; Li B; Shen S; Zhang J; Mansour MR; Young RA; Look AT
Leukemia; 2017 Oct; 31(10):2057-2064. PubMed ID: 28260788
[TBL] [Abstract][Full Text] [Related]
22. Low LEF1 expression is a biomarker of early T-cell precursor, an aggressive subtype of T-cell lymphoblastic leukemia.
Wang M; Zhang C
PLoS One; 2020; 15(5):e0232520. PubMed ID: 32401815
[TBL] [Abstract][Full Text] [Related]
23. TLX1 and NOTCH coregulate transcription in T cell acute lymphoblastic leukemia cells.
Riz I; Hawley TS; Luu TV; Lee NH; Hawley RG
Mol Cancer; 2010 Jul; 9():181. PubMed ID: 20618946
[TBL] [Abstract][Full Text] [Related]
24. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.
Gutierrez A; Sanda T; Grebliunaite R; Carracedo A; Salmena L; Ahn Y; Dahlberg S; Neuberg D; Moreau LA; Winter SS; Larson R; Zhang J; Protopopov A; Chin L; Pandolfi PP; Silverman LB; Hunger SP; Sallan SE; Look AT
Blood; 2009 Jul; 114(3):647-50. PubMed ID: 19458356
[TBL] [Abstract][Full Text] [Related]
25. T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness.
Bardelli V; Arniani S; Pierini V; Di Giacomo D; Pierini T; Gorello P; Mecucci C; La Starza R
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440292
[TBL] [Abstract][Full Text] [Related]
26. PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events.
Mendes RD; Sarmento LM; Canté-Barrett K; Zuurbier L; Buijs-Gladdines JG; Póvoa V; Smits WK; Abecasis M; Yunes JA; Sonneveld E; Horstmann MA; Pieters R; Barata JT; Meijerink JP
Blood; 2014 Jul; 124(4):567-78. PubMed ID: 24904117
[TBL] [Abstract][Full Text] [Related]
27. Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia.
Tesio M; Trinquand A; Ballerini P; Hypolite G; Lhermitte L; Petit A; Ifrah N; Baruchel A; Dombret H; Macintyre E; Asnafi V
Leukemia; 2017 Dec; 31(12):2594-2600. PubMed ID: 28539671
[TBL] [Abstract][Full Text] [Related]
28. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in childhood acute lymphoblastic leukemia.
Jia M; Zhao HZ; Shen HP; Cheng YP; Luo ZB; Li SS; Zhang JY; Tang YM
Int J Lab Hematol; 2015 Oct; 37(5):631-40. PubMed ID: 25955539
[TBL] [Abstract][Full Text] [Related]
30. Translocation t(8;14)(q24;q11) with concurrent PTEN alterations and deletions of STIL/TAL1 and CDKN2A/B in a pediatric case of acute T-lymphoblastic leukemia: A genetic profile associated with adverse prognosis.
Skalska-Sadowska J; Dawidowska M; Szarzyńska-Zawadzka B; Jarmuż-Szymczak M; Czerwińska-Rybak J; Machowska L; Derwich K
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27759908
[TBL] [Abstract][Full Text] [Related]
31. [Mutation and expression of LEF1 in adult acute lymphocytic leukemia and their clinical significance].
Liu J; Guo X; Ge Z; Zhang R; Xu JY; Li M; Wu YJ; Qiao C; Qiu HR; Zhang JF; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1212-6. PubMed ID: 25338559
[TBL] [Abstract][Full Text] [Related]
32. SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines.
Quentmeier H; Schneider B; Röhrs S; Romani J; Zaborski M; Macleod RA; Drexler HG
J Hematol Oncol; 2009 Jan; 2():3. PubMed ID: 19166587
[TBL] [Abstract][Full Text] [Related]
33. The subclonal complexity of STIL-TAL1+ T-cell acute lymphoblastic leukaemia.
Furness CL; Mansur MB; Weston VJ; Ermini L; van Delft FW; Jenkinson S; Gale R; Harrison CJ; Pombo-de-Oliveira MS; Sanchez-Martin M; Ferrando AA; Kearns P; Titley I; Ford AM; Potter NE; Greaves M
Leukemia; 2018 Sep; 32(9):1984-1993. PubMed ID: 29556024
[TBL] [Abstract][Full Text] [Related]
34. RUNX1 promotes cell growth in human T-cell acute lymphoblastic leukemia by transcriptional regulation of key target genes.
Jenkins CE; Gusscott S; Wong RJ; Shevchuk OO; Rana G; Giambra V; Tyshchenko K; Islam R; Hirst M; Weng AP
Exp Hematol; 2018 Aug; 64():84-96. PubMed ID: 29733873
[TBL] [Abstract][Full Text] [Related]
35. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
Kleppe M; Soulier J; Asnafi V; Mentens N; Hornakova T; Knoops L; Constantinescu S; Sigaux F; Meijerink JP; Vandenberghe P; Tartaglia M; Foa R; Macintyre E; Haferlach T; Cools J
Blood; 2011 Jun; 117(26):7090-8. PubMed ID: 21551237
[TBL] [Abstract][Full Text] [Related]
36. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.
Metzeler KH; Heilmeier B; Edmaier KE; Rawat VP; Dufour A; Döhner K; Feuring-Buske M; Braess J; Spiekermann K; Büchner T; Sauerland MC; Döhner H; Hiddemann W; Bohlander SK; Schlenk RF; Bullinger L; Buske C
Blood; 2012 Sep; 120(10):2118-26. PubMed ID: 22815426
[TBL] [Abstract][Full Text] [Related]
37. Does activation of the TAL1 gene occur in a majority of patients with T-cell acute lymphoblastic leukemia? A pediatric oncology group study.
Bash RO; Hall S; Timmons CF; Crist WM; Amylon M; Smith RG; Baer R
Blood; 1995 Jul; 86(2):666-76. PubMed ID: 7605997
[TBL] [Abstract][Full Text] [Related]
38. RUNX1 is required for oncogenic
Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
[TBL] [Abstract][Full Text] [Related]
39. Notch1 co-opts lymphoid enhancer factor 1 for survival of murine T-cell lymphomas.
Spaulding C; Reschly EJ; Zagort DE; Yashiro-Ohtani Y; Beverly LJ; Capobianco A; Pear WS; Kee BL
Blood; 2007 Oct; 110(7):2650-8. PubMed ID: 17585052
[TBL] [Abstract][Full Text] [Related]
40. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.
Peirs S; Matthijssens F; Goossens S; Van de Walle I; Ruggero K; de Bock CE; Degryse S; Canté-Barrett K; Briot D; Clappier E; Lammens T; De Moerloose B; Benoit Y; Poppe B; Meijerink JP; Cools J; Soulier J; Rabbitts TH; Taghon T; Speleman F; Van Vlierberghe P
Blood; 2014 Dec; 124(25):3738-47. PubMed ID: 25301704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
